Aridis has entered an agreement with Kenta Biotech to acquire Kenta’s portfolio of anti-infective human monoclonal antibody (mAb) products and technologies. The portfolio includes six anti-infectives for the treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). Two candidates are in Phase IIa trials for acute pneumonia.   Aridis founder and presi...